The Gastrointestinal (Gl) Cancer Program (Program #6), one of the original programs of the Kimmel Cancer Center at Jefferson, is a multidisciplinary program composed of 25 full and 5 associate members representing 8 departments within Jefferson Medical College (Pathology;Cancer Biology;Family Medicine;Internal Medicine;Medical Oncology;Pharmacology;Radiology;Surgery), the Christiana Care Health System (Helen F. Graham Cancer Center), and Drexel University, whose over-arching goal is to define fundamental mechanisms underlying Gl malignancies which can be translated into diagnostic and therapeutic innovations for managing cancer in patients and populations. Their work is supported by ?~$7.7M in peer-reviewed funding, representing an increase of -75% from $4.4M during the past funding period. Also, program members have published 561 papers, representing almost a doubling compared to the previous funding period. Of those, >17% were intra-programmatic, representing a tripling of the previous rate, and >16% were inter-programmatic. Program members pursue parallel efforts organized along organ based disease processes from discovery through translation to clinical development and application. Members employ common and collaborative experimental paradigms with the goals of (1) defining previously unappreciated molecular, genetic, and epigenetic mechanisms underlying Gl organ-based tumorigenesis, (2) translating defined mechanisms into novel in vitro and in vivo tools to improve prevention, early detection, prognosis, prediction, and risk-stratification in Gl malignancies, (3) defining molecularly targeted therapeutic approaches for cancer prevention, treatment, and control, (4) advancing novel laboratory discoveries into development for clinical trials, and (5) advancing clinically successful diagnostic and therapeutic trials into evidence-based practice for cancer prevention and control across populations. In that context, enrollment of patients in Gl cancer-based clinical trials has increased ~15-fold compared to the past funding period. Members are interactive and cohesive and, under the direction of Program Leaders, coordinate research planning and new research directions with other research programs in the Cancer Center.
The goal of scientists and clinicians in the Gl Cancer Program is to produce new tools to manage patients with esophageal, liver, pancreatic, and colorectal cancer. To do this, they identify molecular mechanisms that cause these diseases and design clinical trials of new diagnostics and therapeutics. These approaches will improve the prevention, diagnosis and treatment of Gl cancers for individual patients and populations.
|Hussain, Maha; Daignault-Newton, Stephanie; Twardowski, Przemyslaw W et al. (2018) Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol 36:991-999|
|Shafi, Ayesha A; Schiewer, Matthew J; de Leeuw, Renée et al. (2018) Patient-derived Models Reveal Impact of the Tumor Microenvironment on Therapeutic Response. Eur Urol Oncol 1:325-337|
|Meyer, Sara E; Muench, David E; Rogers, Andrew M et al. (2018) miR-196b target screen reveals mechanisms maintaining leukemia stemness with therapeutic potential. J Exp Med 215:2115-2136|
|Mazina, Olga M; Mazin, Alexander V (2018) Reconstituting the 4-Strand DNA Strand Exchange. Methods Enzymol 600:285-305|
|Magee, Michael S; Abraham, Tara S; Baybutt, Trevor R et al. (2018) Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases. Cancer Immunol Res 6:509-516|
|Chervoneva, Inna; Freydin, Boris; Hyslop, Terry et al. (2018) Modeling qRT-PCR dynamics with application to cancer biomarker quantification. Stat Methods Med Res 27:2581-2595|
|Capparelli, Claudia; Purwin, Timothy J; Heilman, Shea A et al. (2018) ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma. Cancer Res 78:5680-5693|
|Nevler, Avinoam; Muller, Alexander J; Cozzitorto, Joseph A et al. (2018) A Sub-Type of Familial Pancreatic Cancer: Evidence and Implications of Loss-of-Function Polymorphisms in Indoleamine-2,3-Dioxygenase-2. J Am Coll Surg 226:596-603|
|Peng, Weidan; Furuuchi, Narumi; Aslanukova, Ludmila et al. (2018) Elevated HuR in Pancreas Promotes a Pancreatitis-Like Inflammatory Microenvironment That Facilitates Tumor Development. Mol Cell Biol 38:|
|Waldman, Scott A; Camilleri, Michael (2018) Guanylate cyclase-C as a therapeutic target in gastrointestinal disorders. Gut 67:1543-1552|
Showing the most recent 10 out of 807 publications